Logotipo do repositório

A comprehensive model for assessing and classifying patients with thrombotic microangiopathy: the TMA-INSIGHT score

dc.contributor.authorAddad, Vanessa Vilani
dc.contributor.authorPalma, Lilian Monteiro Pereira
dc.contributor.authorVaisbich, Maria Helena
dc.contributor.authorPacheco Barbosa, Abner Mácola [UNESP]
dc.contributor.authorda Rocha, Naila Camila
dc.contributor.authorde Almeida Cardoso, Marilia Mastrocolla
dc.contributor.authorde Almeida, Juliana Tereza Coneglian
dc.contributor.authorde Paula de Sordi, Monica Ap
dc.contributor.authorMachado-Rugolo, Juliana
dc.contributor.authorArantes, Lucas Frederico
dc.contributor.authorde Andrade, Luis Gustavo Modelli
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionHealth Technology Assessment Center of Hospital das Clínicas - HCFMB
dc.date.accessioned2025-04-29T20:17:21Z
dc.date.issued2023-12-01
dc.description.abstractBackground: Thrombotic Microangiopathy (TMA) is a syndrome characterized by the presence of anemia, thrombocytopenia and organ damage and has multiple etiologies. The primary aim is to develop an algorithm to classify TMA (TMA-INSIGHT score). Methods: This was a single-center retrospective cohort study including hospitalized patients with TMA at a single center. We included all consecutive patients diagnosed with TMA between 2012 and 2021. TMA was defined based on the presence of anemia (hemoglobin level < 10 g/dL) and thrombocytopenia (platelet count < 150,000/µL), signs of hemolysis, and organ damage. We classified patients in eight categories: infections; Malignant Hypertension; Transplant; Malignancy; Pregnancy; Thrombotic Thrombocytopenic Purpura (TTP); Shiga toxin-mediated hemolytic uremic syndrome (STEC-SHU) and Complement Mediated TMA (aHUS). We fitted a model to classify patients using clinical characteristics, biochemical exams, and mean arterial pressure at presentation. Results: We retrospectively retrieved TMA phenotypes using automatic strategies in electronic health records in almost 10 years (n = 2407). Secondary TMA was found in 97.5% of the patients. Primary TMA was found in 2.47% of the patients (TTP and aHUS). The best model was LightGBM with accuracy of 0.979, and multiclass ROC-AUC of 0.966. The predictions had higher accuracy in most TMA classes, although the confidence was lower in aHUS and STEC-HUS cases. Conclusion: Secondary conditions were the most common etiologies of TMA. We retrieved comorbidities, associated conditions, and mean arterial pressure to fit a model to predict TMA and define TMA phenotypic characteristics. This is the first multiclass model to predict TMA including primary and secondary conditions.en
dc.description.affiliationDepartment of Internal Medicine - UNESP Univ Estadual Paulista, Rubião Jr, s/n
dc.description.affiliationDepartment of Pediatrics Universidade Estadual de Campinas, R. Tessália Vieira de Camargo, 126 - Cidade Universitária
dc.description.affiliationPediatric Nephrology Service Child Institute University of São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 647, SP
dc.description.affiliationHealth Technology Assessment Center of Hospital das Clínicas - HCFMB
dc.description.affiliationUnespDepartment of Internal Medicine - UNESP Univ Estadual Paulista, Rubião Jr, s/n
dc.identifierhttp://dx.doi.org/10.1186/s12959-023-00564-6
dc.identifier.citationThrombosis Journal, v. 21, n. 1, 2023.
dc.identifier.dimensionspub.1166262937
dc.identifier.doi10.1186/s12959-023-00564-6
dc.identifier.issn1477-9560
dc.identifier.orcid0000-0002-1684-2574
dc.identifier.orcid0000-0001-8865-0398
dc.identifier.orcid0000-0002-6231-5425
dc.identifier.orcid0000-0002-4946-5189
dc.identifier.orcid0000-0002-0230-0766
dc.identifier.orcid0000-0003-3984-4959
dc.identifier.orcid0000-0002-6084-7831
dc.identifier.orcid0000-0002-0334-8470
dc.identifier.orcid0000-0002-9322-3849
dc.identifier.pmcidPMC10664252
dc.identifier.pmid37993892
dc.identifier.scopus2-s2.0-85177560073
dc.identifier.urihttps://hdl.handle.net/11449/309963
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.ispartofThrombosis Journal
dc.rights.accessRightsAcesso abertopt
dc.rights.sourceRightsoa_all
dc.rights.sourceRightsgold
dc.sourceScopus
dc.sourceDimensions
dc.subjectAtypical hemolytic uremic syndrome
dc.subjectComplement mediated TMA
dc.subjectShiga toxin-mediated hemolytic uremic syndrome
dc.subjectThrombotic microangiopathy
dc.subjectThrombotic Thrombocytopenic Purpura
dc.titleA comprehensive model for assessing and classifying patients with thrombotic microangiopathy: the TMA-INSIGHT scoreen
dc.typeArtigopt
dspace.entity.typePublication
relation.isAuthorOfPublicationc3f0df74-75f1-4974-a6a9-dff901482abf
relation.isAuthorOfPublicationec1798fd-dba0-4fe1-a6c9-b71c2aec0c6f
relation.isAuthorOfPublication38db9309-8cd5-4cb1-8a2e-dc0a56d6c5e9
relation.isAuthorOfPublication.latestForDiscoveryc3f0df74-75f1-4974-a6a9-dff901482abf
relation.isAuthorOfPublication.latestForDiscoveryec1798fd-dba0-4fe1-a6c9-b71c2aec0c6f
relation.isAuthorOfPublication.latestForDiscovery38db9309-8cd5-4cb1-8a2e-dc0a56d6c5e9
unesp.author.orcid0000-0002-9322-3849[1]
unesp.author.orcid0000-0002-0334-8470[2]
unesp.author.orcid0000-0002-6084-7831[3]
unesp.author.orcid0000-0003-3668-8911[4]
unesp.author.orcid0000-0002-1684-2574[5]
unesp.author.orcid0000-0002-6231-5425[6]
unesp.author.orcid0000-0001-8865-0398[7]
unesp.author.orcid0000-0003-3621-3414[8]
unesp.author.orcid0000-0003-3984-4959[9]
unesp.author.orcid0000-0002-4946-5189[10]
unesp.author.orcid0000-0002-0230-0766[11]

Arquivos

Coleções